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Pregnancy and Lactation
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Department of Environmental Health Sciences, School of Public Health and Health Sciences, University
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Hormones and endocrine-disrupting chemicals are generally thought to have permanent “organizational” effects when exposures occur during development but not adulthood. Yet, an increasing number
of studies have shown that pregnant females are disrupted by endocrine-disrupting chemical exposures,
with some effects that are permanent. Here, we examined the long-term effects of exposure to oxybenzone, an estrogenic chemical found in sunscreen and personal care products, on the morphology of
the mammary gland in mice exposed during pregnancy and lactation. Female mice were exposed to
vehicle or 30, 212, or 3000 mg oxybenzone/kg/d, from pregnancy day 0 until weaning. A nulliparous
group, receiving vehicle treatment, was also evaluated. Mammary glands were collected 5 weeks after
involution for whole-mount, histological, immunohistochemical, and molecular analyses. Exposure to
3000 mg oxybenzone/kg/d induced permanent changes to ductal density that was significantly different
from both the nulliparous and vehicle groups. The two highest doses of oxybenzone similarly induced an
intermediate phenotype for expression of progesterone receptor. A monotonic, dose-dependent increase
in cell proliferation was also observed in the oxybenzone-treated females, becoming statistically significant at the highest dose. Finally, oxybenzone exposure induced an intermediate phenotype for Esr1
expression in all oxybenzone-treated groups. These data suggest that oxybenzone, at doses relevant to
human exposures, produces long-lasting alterations to mammary gland morphology and function.
Further studies are needed to determine if exposure to this chemical during pregnancy and lactation will
interfere with the known protection that pregnancy provides against breast cancer.
Copyright © 2018 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution NonCommercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-ncnd/4.0/).
Freeform/Key Words: benzophenone, estrogen receptor, involution, parity, vulnerable period,
xenoestrogen

The mammary gland is a unique organ that grows and changes rapidly throughout a female’s
lifetime, including during puberty when the ductal tree reaches its full size and then again
during pregnancy when differentiation and growth support lactation. After the initial development of the mammary gland in the embryonic stage, much of the growth and reorganization of the mammary gland that occurs at or after puberty is hormone dependent [1].
During early pregnancy, estrogen produced by the corpus luteum induces ductal morphogenesis and is important for the induction of the progesterone receptor (PR) in mammary
epithelial cells [2], which is mediated by estrogen receptor (ER)a [3]. Although ERa is highly
expressed in adult mammary epithelial cells, ERa expression diminishes in pregnancy and is
again highly expressed during lactation [4]. The hormones of pregnancy induce rapid ductal
Abbreviations: 95P, 95th percentile; BPA, bisphenol A; ER, estrogen receptor; H&E, hematoxylin and eosin; LD, lactational day; LSD,
least significant difference; NOAEL, no-observed adverse-effect level; PR, progesterone receptor; qRT-PCR, quantitative RT-PCR;
Stat, signal transducer and activator of transcription; TDI, tolerable daily intake.
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side-branching, followed by development of lobuloalveolar units, e.g., the differentiated
epithelial structures that develop during pregnancy and are milk-secreting compartments.
These structures ultimately fill the fat pad and produce milk [5]. Progesterone and prolactin
induce alveolar and lobuloalveolar development by stimulating epithelial proliferation,
causing branching and reorganization of ducts [1, 6]. Late in pregnancy, PR expression
decreases and is absent entirely in lactation [2, 7, 8]. Proliferation is absent during mid and
late lactation, because the mammary gland has already grown to accommodate milk production [7, 9].
As the pups grow and begin to eat solid foods, they consume less milk, eventually leading to
natural weaning. With the loss of suckling, milk accumulates in the lumen of alveolar
structures, inducing mechanical strain; the presence of milk in the alveoli causes systemic
concentrations of lactogenic hormones to fall [10]. Once this occurs, the mammary gland
undergoes involution, which progresses in two distinct phases. In the first phase, massive
numbers of secretory cells undergo apoptosis; if suckling occurs, this phase is reversible. In the
second phase, the mammary gland undergoes extensive remodeling and reorganization to
return to a prepregnant appearance; this phase is irreversible [11]. The process of involution
requires macrophages, expression of a number of genes [e.g., signal transducer and activator of
transcription (Stat)3, Fas ligand, and TGF-b/Wnt5a] [12], and the inactivation of Stat5a and
Stat5b, which halt prolactin signaling and reduce cell survival [13]. After involution, the
mammary gland returns to a state similar to a nulliparous adult female, but some distinguishing features remain. For example, the differentiated cells produced during pregnancy
comprise a new mammary epithelial cell population that is molecularly and physiologically
distinct from the mammary epithelial cells present before pregnancy; these parity-induced
epithelial cells serve as progenitors of lobuloalveolar cells [14] and persist at the terminal ends
of ducts [15], allowing the gland to respond more rapidly during subsequent pregnancies.
A woman’s lifetime exposure to estrogen is a risk factor for breast cancer; early menarche
and late menopause increase risk [16]. Furthermore, exposures to heightened levels of estrogens in utero, such as those experienced by twins or after pharmaceutical treatment with
estrogens, such as diethylstilbestrol, also increase breast cancer risk in females exposed in
the womb [17–21]. Yet, pregnancy with high levels of circulating estrogens is known to reduce
breast cancer risk in adult women [22]; women with an early age of first pregnancy [23, 24]
and women who breastfeed for .12 months experience the greatest reductions in breast
cancer risk, suggesting that involution involves protective events for the mammary gland [6,
25–27]. It has been hypothesized that pregnancy-associated protection from breast cancer
arises as a result of the higher degree of differentiation of mammary tissues induced by
pregnancy hormones and the diminished epithelial cell proliferation after involution [23, 28,
29]. Over 200 genes differ in their expression between breast cells collected from nulliparous
and parous women, indicative of the long-term, permanent effects that pregnancy has on the
mammary gland [30].
Because of the important role for lifelong estrogen exposure in determining risk for
mammary cancer, recent studies have evaluated the hypothesis that exposures to estrogenic
environmental chemicals could disrupt mammary gland development and ultimately influence mammary cancer risk [31, 32]. Most of these studies have evaluated “organizational”
exposures, e.g., those occurring during gestation, which induce changes that persist even
when the exposure ends [33–35]. Exposures during adulthood are generally deemed “activational,” as the changes are reversible; when the exposures cease, the effects are expected to
as well. Despite these common assumptions, xenoestrogen exposures during pregnancy and
lactation can induce permanent, organizational effects. For example, women that were
prescribed diethylstilbestrol during pregnancy have an increased risk of breast cancer
compared with unexposed women [36]. Xenoestrogen exposures are therefore important to
consider, not only during gestation but also in adults as well, as they may contribute to
lifelong estrogen exposure.
For many decades, scientists believed that the high levels of sex hormones present during
pregnancy meant that xenoestrogens in the environment were not relevant to the health of
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the mammary gland; this presumption was based on an expectation that “low-level” exposures to “weak” estrogens could not produce effects when the concentrations of endogenous
hormones were dramatically higher. Recent work has shown that the mammary gland is, in
fact, susceptible to xenoestrogen exposures during pregnancy and lactation. Mammary
glands collected from female mice exposed, during pregnancy and lactation, to low doses of
bisphenol S, an estrogenic compound, exhibited morphological deficits consistent with early
involution [7]. Other studies have similarly demonstrated that adult exposures to xenoestrogens permanently affect the health of the mother. For example, female mice exposed to
bisphenol A (BPA) during pregnancy gave birth to male offspring that developed glucose
intolerance, heightened insulin resistance, and altered pancreatic islets of Langerhans in
adulthood [37]. The mothers that were only exposed to BPA during pregnancy also developed
similar effects, months after exposures ended; the dams weighed more and had higher insulin, leptin, triglyceride, and glycerol levels in the blood and greater insulin resistance,
4 months postpregnancy [37].
Oxybenzone (benzophenone-3), a common ingredient in consumer products as a result of
its use as an ultraviolet filter [38], is an ERa agonist [39, 40]; it does not appear to be an
agonist for ERb [41]. Several metabolites of oxybenzone are also estrogenic [42]. Oxybenzone
is also antiestrogenic and antiandrogenic in some contexts [38]. The main source of human
exposure is through sunscreen [43] and other personal care products, including hair spray,
cosmetics (often from products with sunscreen agents in them, such as lotions, lipsticks, and
shampoo), fragrances, and skin care products; it is also found as a UV protectant in carpets,
furniture, and clothing [43–45]. Oxybenzone is absorbed dermally and orally from these
products before it is metabolized and excreted in urine [43, 44]. Human exposure to oxybenzone is widespread if not ubiquitous. Data from the US Centers for Disease Control and
Prevention, National Health and Nutrition Examination Survey biomonitoring study,
revealed detectable levels of oxybenzone in the urine of 100% of pregnant and 98% of
nonpregnant women [46]. Oxybenzone had one of the highest concentrations of nonpersistent
chemicals measured in urine in pregnant women, increasing concerns about exposures to this
population. Importantly, oxybenzone is present in human urine year round, as evidenced by a
Danish children’s cohort, where it was measured in urine samples collected during the winter
with minimal sun and short days [45]. Finally, several studies have evaluated associations
between human exposure to oxybenzone and adverse health outcomes. Prenatal oxybenzone
exposure was positively associated with body weight and head circumference in boys but
negatively associated with body weight in girls at birth [43, 47].
In this study, we evaluated the effects of oxybenzone on mice exposed during pregnancy and
lactation. Because it is an ERa agonist, we hypothesized that exposure to oxybenzone during
pregnancy and lactation would disrupt morphology, cell proliferation, gene expression, and
hormone receptor expression in the mammary gland and that these effects would persist long
after exposures ceased. One prior study—a National Toxicology Program carcinogenesis and
toxicology study—examining the effects of oxybenzone on the mammary gland reported that
2 years of exposure to oxybenzone (at doses ranging from 15 to 65 mg/kg/d) decreased the
incidence of fibroadenomas in the female F344/N rat, possibly as a result of inhibition of steroid
sulfatase (which regulates the formation of estrone and its conversion to estradiol) [48]. Here,
we present evidence that the mammary gland is a sensitive target to oxybenzone when exposures occur during pregnancy and lactation, a window of susceptibility that is poorly studied.

1. Methods
A. Animals—Acute Exposure Study
Six- to 8-week-old female Balb/C mice were ovariectomized, given 1 week to recover from
surgery and for ovarian hormone levels to drop. Females were then randomly assigned to one
of three treatment groups. For 4 days, females were weighed and orally dosed daily by pipet
with corn oil, 17b-estradiol dissolved in corn oil or oxybenzone dissolved in corn oil. Doses
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were 250 mg 17b-estradiol/kg/d and 3000 mg oxybenzone/kg/d. On the day after the final oral
treatment, mice were euthanized by CO2 inhalation. The uterus was removed, trimmed of fat,
and weighed with an analytical balance. It was then snap frozen for quantitative RT-PCR
(qRT-PCR) analysis as described later.
B. Animals—Chronic Study (Pregnancy, Lactation, and Postinvolution)
Six- to 8-week-old female Balb/C mice were mated with males and housed in polysulfone
cages with food (LabDiet Chow 5058; LabDiet, St. Louis, MO) and water provided ad libitum.
The animals were maintained at the University of Massachusetts Amherst, Amherst Animal
Facility, in temperature- and light-controlled conditions (12 hours light, 12 hours dark). All
experimental procedures were approved by the University of Massachusetts Institutional
Animal Care and Use Committee.
Before mating, females were randomly assigned to one of five treatment groups using
statistical software to give a normal distribution of body weight to each treatment group.
From pregnancy day 0 until the day before weaning [on lactational day (LD) 21], females were
weighed and orally dosed daily by pipet with either corn oil or oxybenzone dissolved in corn
oil. Three doses of oxybenzone were used. One group of pregnant female mice received the
lowest dose (30 mg/kg/d), which was chosen because it is the tolerable daily intake (TDI) of
oxybenzone [49]. The middle dose (212 mg/kg/d) was chosen because it approximates exposures to oxybenzone in pregnant women in the 95th percentile (95P) of exposure. This was
calculated by multiplication of the concentrations reported in the 95P of pregnant women in
the United States with the average daily urinary output during pregnancy (2.2 L) and division of 70 kg body weight [46]. The highest dose (3000 mg/kg/d) was chosen because it is the
toxicological no-observed adverse-effect level (NOAEL) dose for oxybenzone [49, 50] based
on developmental and reproductive toxicity assays. Doses ~10 times higher are needed to
produce urine concentrations in rodents that replicate human urine concentrations, suggesting that all three doses are environmentally relevant (see [48] and unpublished data).
The vehicle group received oil instead of oxybenzone for the same dosing period. A second
control group of nulliparous female mice was housed under the same conditions and was
treated the same, receiving oil instead of oxybenzone, for the same length of time. The
oxybenzone dose (and volume of vehicle, equivalent to 1 mL/g body weight) was adjusted for
dam body weight daily. The oxybenzone used was .99% pure.
Dams delivered naturally (birth designated LD0) and were allowed to nurse normally. On
LD21, the pups were weaned, and the dams were moved to new cages. Dams were group
housed (two females per cage) with other animals from the same treatment group for 5 weeks
after weaning to allow full involution of the mammary gland. At ~17 to 20 weeks of age
(depending on efficiency of pregnancy), the females were euthanized for tissue collection. A
schematic summarizing the exposure period and experimental design is shown in Fig. 1.
C. Euthanasia and Tissue Collection
At 5 weeks postweaning, female mice were euthanized via CO2 inhalation. From every dam,
the left and right third (pectoral/thoracic) mammary glands were dissected from the skin,
spread on a glass slide (Thermo Fisher Scientific, Waltham, MA), and fixed in neutralbuffered formalin (10%; Thermo Fisher Scientific) overnight (standard whole-mount preparation). The right fourth inguinal mammary gland was fixed in neutral-buffered formalin
(10%) overnight for paraffin embedding and histology. The left fourth inguinal mammary
gland was dissected from the skin, the lymph node was removed, and it was then flash frozen
on dry ice and stored at 280°C for qRT-PCR analyses.
D. Whole-Mount Preparation and Analysis
After fixation, whole-mounted mammary glands were processed through an alcohol series,
defatted with toluene, stained with carmine alum, dehydrated in an alcohol and xylene series,
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Figure 1. Schematic of exposure period and experimental design. Dotted gray bar indicates
the exposure period for the adult female mice (pregnancy day 0 through LD20). Animals in
the nulliparous treatment group were treated with vehicle for the same length of time as
other groups but were not mated. Samples were collected from all parous females, 5 weeks
after weaning, and from age-matched nulliparous females. All females were unexposed (to
either vehicle or oxybenzone) for the 5-week period.

and preserved in k-pax heat-sealed bags (Thermo Fisher Scientific) with methyl salicylate
(Acros Organics, Morris Plains, NJ) [51]. Two digital images of whole-mount mammary
glands (one from the left; one from the right third pectoral glands) were obtained using an
AxioImager dissection microscope (Carl Zeiss Microscopy, Jena, Germany) at 330 magnification and a Zeiss high-resolution color camera. To evaluate mammary gland morphology,
ZEN software (Carl Zeiss Microscopy) was used to measure ductal density [51]. A 13 3 16 grid
(180 crosshairs, 0.3 mm apart) was placed on each image, and the fraction of crosshairs that
fell on ducts was quantified and averaged for the two images for each sample.
E. Tissue Processing and Histological Staining
To prepare mammary tissue for paraffin sections, fixed excised tissue was washed in PBS,
dehydrated through a series of alcohols, and embedded with paraffin (Leica Biosystems,
Richmond, IL) under vacuum. Sections (5 mm) were cut on a Fisher rotary microtome and
mounted on positively charged slides (Thermo Fisher Scientific). These sections were used for
histological and immunohistochemical analyses.
For histological evaluations, slides were deparaffinized with xylene and a series of alcohols, stained with Harris’ hematoxylin and eosin (H&E; Thermo Fisher Scientific),
dehydrated, and mounted with permanent mounting media (Thermo Fisher Scientific).
Digital images were collected using a Zeiss Axio Oberserver.Z1 inverted microscope, a 310
objective, and a high-resolution color camera (Carl Zeiss Microscopy). To quantify the fraction
of the mammary gland comprised of epithelium, one entire longitudinal section of mammary
gland was imaged. Three images were randomly selected and an identical 10 3 13 grid
(108 crosshairs, 100 mm apart) was placed on each image, and the number of crosshairs on
epithelial tissue was recorded, as well as the crosshairs that did not fall on mammary tissue
at all. The values for the three images were averaged for each sample.
F. Mammary Gland Immunohistochemistry
Expression of four markers was evaluated using standard methods for immunohistochemistry and commercial antibodies, including rabbit anti-ERa (Cat. #06-935; MilliporeSigma,
St. Louis, MO [52]); rabbit anti-Ki67 (Cat. #RM-9106-S1; Thermo Fisher Scientific [53]), a
marker of proliferation; rabbit anti-PR (Cat. #ab131486; Abcam, Cambridge, MA [54]); and
rabbit anti-Wnt5a (Cat. #ab174963; Abcam [55]). See Table 1 for a summary of these antibodies. In brief, sections were deparaffinized, hydrated through a series of alcohols,
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Table 1. Information About Antibodies
Peptide/
Protein
Target

Antigen
Sequence
(if Known)

Name of
Antibody

Manufacturer,
Catalog No.

ERa

Anti-ERa (C1355)

Ki67

Ki67

Progesterone
receptor
Wnt5a
Secondary

Anti-PR

EMD Millipore,
06-935
Thermo Fisher
Scientific,
RM-9106-S1
Abcam, ab131486

Anti-Wnt5a
Biotinylated goat
anti-rabbit IgG

Abcam, ab174963
Abcam, ab64256

Species; Raised
in Polyclonal
or Monoclonal

Dilution
Used

RRID

Rabbit; polyclonal

1:1000

AB_31035 [52]

Rabbit; monoclonal

1:1000

AB_149792 [53]

Rabbit; polyclonal

1:500

AB_11156044 [54]

Rabbit; polyclonal
Goat; polyclonal

1:500
Ready to use
(5 mg/mL)

AB_2725803 [55]
AB_2661852 [56]

microwaved in 10 mM citrate buffer (pH 6) for antigen retrieval, and treated with hydrogen
peroxide to quench endogenous peroxidases. Nonspecific binding was blocked with 1% milk
protein in 5% normal goal serum (Cell Signaling Technology, Danvers, MA). Sections were
incubated with primary antibodies (see Table 1 for concentrations) at 4°C for 14 to 16 hours
and washed and incubated with secondary antibody (goat anti-rabbit, Cat. #ab64256; Abcam [56]),
followed by streptavidin peroxidase complex (Abcam, Cat# ab64269). Diaminobenzidene chromogen (Cat. #ab64238; Abcam) was used to visualize reactions. Sections were counterstained
with Harris hematoxylin (Thermo Fisher Scientific). Each immunohistochemical run included a
negative control in which the primary antibody was replaced with 5% normal goat serum.
Nonoverlapping images were taken of each sample for ERa, Ki67, and PR at 340 magnification with a Zeiss Axio Observer.Z1 inverted microscope and 320 magnification for
Wnt5a. Expression of ERa and PR was evaluated by counting at least 500 epithelial cells in
two to four separate fields. Expression of Ki67 was evaluated by counting at least 800 epithelial cells in four separate fields. Expression of ERa, Ki67, and PR was expressed as a
percent ratio of the total number of epithelial cells evaluated.
Wnt5a expression was assessed qualitatively. For both epithelium and stroma, a representative image was chosen for low, medium, and high expression of Wnt5a and assigned a
number (low = 1, medium = 2, and high = 3). Three images of epithelium and three images of
stroma were assessed per sample for Wnt5a expression. For each image of mammary tissue
incubated with antibodies for Wnt5a, a number was assigned from 0 (no expression, resembling the negative control) to 3 by comparing it with the representative images. The
scores for each image were averaged (to get average scores for epithelium and stroma) to
characterize Wnt5a expression for each mammary gland.
G. qRT-PCR
Total RNA was extracted from uterine tissue (in the acute exposure study) or mammary
glands (in the pregnancy/lactation/involution study) of individual mice using Trizol reagent (Thermo Fisher Scientific) and a BeadBug microtube homogenizer (MilliporeSigma),
according to the manufacturers’ instructions. RNA integrity was evaluated using a bioanalyzer, and total RNA was quantified by UV spectrophotometry (Nanodrop 1000; Thermo
Fisher Scientific). RNA (1 mg) from each sample was reverse transcribed to cDNA using
reverse transcription (Thermo Fisher Scientific). The FastStart Universal SYBR Green
Master kit (Roche Diagnostics, Indianapolis, IN) was used for the qRT-PCRs, along with 1 mL
cDNA and 300 nM forward and 300 nM reverse primers for each target gene. b-Actin was
used as a housekeeping gene. Every sample was run in duplicate for each gene target. The
thermal profile was as follows: 10 minutes at 95°C and 40 cycles of 15 seconds at 95°C,
30 seconds at 60°C, and 15 seconds at 72°C; a melting-curve analysis was conducted to identify
nonspecific products. Relative quantification was determined using the DDCt method to correct
for differences in b-actin [57]. Primer sequences are reported in Table 2.
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Table 2. Information About Primers
Gene
ERa (Esr1)
ERb (Esr2)
PR (ProgR) total
Wnt5a
b-Actin

Forward Primer Sequence

Reverse Primer Sequence

TGC AAT GAC TAT GCC TCT GG (782-801)
TGT GTG TGA AGG CCA TGA TT
AAA GGA TCC GCA GGT TCT C
GAA TCC CAT TTG CAA CCC CTC ACC
CAC ACC CGC CAC CAG TTC GC (89-108)

CTC CGG TTC TTG TCA ATG GT (921-902)
TCT TCG AAA TCA CCC AGA CC
GTT CCA TCT TCC AGC GGA TA
GCT CCT CGT GTA CAT TTT CTG CCC
TTG CAC ATG CCG GAG CCG TT (162-143)

Abbreviation: ProgR, progesterone receptor.

H. Statistical Analysis
Mouse experiments were run in two separate batches. All treatment groups were included in
both batches. After running two-way ANOVA to determine if batches significantly influenced
outcomes, the batches were combined. For some outcomes, only dams from batch 1 were
evaluated (e.g., qRT-PCR and immunohistochemistry). Additional outcomes evaluated in
batch 2 animals will be presented in future manuscripts.
Morphological, histological, and immunohistochemical analyses were conducted by observers
blind to the treatment groups. Data were analyzed using SPSS Version 24 (IBM, Inc., Armonk,
NY). Continuous variable data were analyzed using one-way ANOVA General Linear Model
analyses with treatment as the independent variable, followed by Fisher least significant difference (LSD) post hoc tests. Data were considered statistically significant at P , 0.05. Graphs
illustrate means 6 SE unless otherwise stated. For whole-mount evaluations, sample sizes were
the following: vehicle (n = 14), nulliparous (n = 12), 30 mg oxybenzone/kg/d (TDI; n = 13), 212 mg
oxybenzone/kg/d (95P; n = 14), and 3000 mg oxybenzone/kg/d (NOAEL; n = 14). For histological,
immunohistochemical, and qRT-PCR analyses, sample sizes were the following: vehicle (n = 7),
nulliparous (n = 5), 30 mg oxybenzone/kg/d (TDI; n = 6), 212 mg oxybenzone/kg/d (95P; n = 7), and
3000 mg oxybenzone/kg/d (NOAEL; n = 7). For acute exposure studies, sample sizes were the
following: vehicle (n = 6), 3000 mg oxybenzone/kg/d (n = 6), and 250 mg 17b-estradiol/kg/d (n = 4).

2. Results
A. Acute Exposures to Oxybenzone
Prior studies have demonstrated that oxybenzone and its metabolites are estrogenic, antiestrogenic, and antiandrogenic in different in vitro contexts [38]. Additional studies in immature rats have shown that high doses of oxybenzone (.1000 mg/kg/d) are needed to alter
uterine weight, a classical read-out of estrogenic activity [58]. Effects of acute (4-day) exposures
to oxybenzone (3000 mg/kg/d, the high dose tested in the remainder of this study) were examined in ovariectomized adult females. Unlike 17b-estradiol, oxybenzone did not alter the
weight of the uterus (Fig. 2A). It did, however, produce modest but substantial effects on
expression of ERa (Esr1) in the uterus, consistent with an estrogenic response (Fig. 2B). In
contrast to acute exposures to 17b-estradiol, acute oxybenzone exposures did not alter morphology or proliferation in the mammary gland (data not shown).
B. Pregnancy Outcomes and Body Weight
Pregnancy outcomes were evaluated in all parous females from the four treatment groups
(vehicle, oxybenzone-TDI, oxybenzone-95P, and oxybenzone-NOAEL). There were no substantial effects of treatment on the number of pups that were born (present on the day of
parturition) or the number of pups that survived to weaning (Fig. 3A and 3B). Oxybenzone
exposure induced modest changes to the length of gestation, measured as the time between
when a sperm plug was observed and when the pups were born, although these differences
were not statistically significant (Fig. 3C).
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Figure 2. Acute effects of oxybenzone on ER-mediated endpoints in vivo. (A) Unlike acute
exposure to 17b-estradiol, acute exposure to 3000 mg oxybenzone/kg/d did not induce an
increase in uterine weight. (B) Acute exposure to 17b-estradiol or oxybenzone increased
expression of ERa (Esr1) in the uterus. Different letters indicate significant differences
among groups, P , 0.05, Fisher LSD post hoc after significant ANOVA.

Dams had similar body weights in all treatment groups at the start of the study by design,
as body weight was used to distribute females equally between treatment groups. Body
weights were also indistinguishable between groups just before parturition (Fig. 3D).
C. Oxybenzone Alters Mammary Gland Morphology and Histomorphology
To determine whether exposure to oxybenzone during pregnancy and lactation could affect the
long-term morphology of the mammary gland, we examined whole-mount mammary glands
collected from female mice, 5 weeks after weaning, once mammary gland involution was
complete (Fig. 4A). With the use of unbiased stereology methods, we calculated the density of
epithelial tissue in each mammary gland. As expected, nulliparous females had significantly
lower ductal density compared with the parous vehicle-exposed females (P , 0.001, Fisher
LSD; Fig. 4B). The nulliparous females were also significantly different from all three oxybenzone treatment groups (P , 0.001, Fisher LSD; Fig. 4B). Neither the oxybenzone-TDI nor
the oxybenzone-95P groups were statistically different from the vehicle-exposed group.
However, the oxybenzone-NOAEL-treated females had mammary glands with significantly
lower ductal densities than the vehicle group (P , 0.001, Fisher LSD), consistent with an
intermediate phenotype between nulliparous and parous mammary glands (Fig. 4B).
We further investigated this finding by observing whether oxybenzone exposure could
affect the histology of the mammary gland. We examined paraffin sections after H&E
staining to quantify the volume fraction of epithelium in a single longitudinal section through
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Figure 3. Oxybenzone has only minor effects on pup weight and survival and no effects on
dam weight during pregnancy. (A) Oxybenzone produced no substantial differences in the
number of pups born or (B) the number of pups surviving to weaning. (C) No substantial
effects of oxybenzone on gestational length were observed. (D) By design, no differences in
dam body weight were observed at the start of the experiment (data not shown) or at the
heaviest point during pregnancy.

the gland (Fig. 4C). Nulliparous mammary glands had significantly less epithelium compared
with the vehicle parous mammary glands, as expected (P = 0.001, Fisher LSD; Fig. 4D). The
nulliparous glands also had significantly less epithelium compared with the oxybenzone-95P
and oxybenzone-NOAEL groups (P , 0.05, Fisher LSD; Fig. 4D). The oxybenzone-TDI
mammary glands were not statistically different from either the nulliparous or the vehicle parous mammary glands, consistent with an intermediate phenotype (Fig. 4D).
D. Oxybenzone Alters Proliferation in Mammary Epithelium
Proliferation is high in the mammary gland epithelium during pregnancy and then low during
both lactation and involution when the gland is either producing milk or when the epithelial cells
are rapidly dying [2]. To evaluate whether maternal exposures to oxybenzone affect proliferation
in the mammary gland after involution, we quantified expression of Ki67, a marker of proliferation, in the mammary epithelium (Fig. 5A). Although parity decreased Ki67 expression
(parous vehicle-exposed vs nulliparous females), this difference was not statistically significant (Fig. 5B). Interestingly, there was a dose-dependent increase in Ki67 expression in the
oxybenzone-treated females, with a statistically significant increase in the oxybenzone-NOAELtreated females compared with the vehicle parous females (P = 0.01, Fisher LSD; Fig. 5A and 5B).
E. Oxybenzone Alters Expression of Esr1 in Mammary Epithelium
ERa is highly expressed in mammary epithelium during adulthood; it diminishes during
pregnancy and then returns to higher expression levels during lactation [4]. We first evaluated whether maternal exposure to oxybenzone alters expression of Esr1, the gene encoding
ERa, in the mammary gland after involution. qRT-PCR analyses revealed significant differences in Esr1 expression as a result of parity; expression of Esr1 was significantly diminished in mammary epithelium from parous vehicle-exposed females compared with
nulliparous females (P , 0.05, Fisher LSD; Fig. 6A). Yet, expression of Esr1 in all three
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Figure 4. Oxybenzone alters mammary gland morphology and histomorphology. (A)
Representative whole-mount mammary gland images collected from females in each
treatment group. Original scale bars, 0.5 mm. (B) Quantification of ductal density reveals
an intermediate phenotype in the oxybenzone-NOAEL treatment group. (C) Representative
H&E sections of mammary glands collected from females of each treatment group. Original
scale bars, 100 mm. (D) Quantification of volume fraction epithelium reveals an intermediate
phenotype in the TDI-treated group. In all panels, different letters indicate significant
differences among groups, P , 0.05, Fisher LSD post hoc after significant ANOVA.

oxybenzone-treated groups was indistinguishable from both the nulliparous and the parous
vehicle-exposed animals, consistent with an intermediate phenotype (Fig. 6A).
We next evaluated expression of ERa protein using immunohistochemistry (Fig. 6B).
There was no effect of parity on the percentage of epithelial cells expressing ERa (Fig. 6C).
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Figure 5. Oxybenzone alters mammary gland cell proliferation. (A) Immunohistochemistry
for Ki67, a marker of proliferation. Original scale bars, 20 mm; red arrows indicate positive
cells. (B) Quantification of Ki67 expression in the mammary gland reveals a monotonic dosedependent response that becomes significant in the oxybenzone-NOAEL treatment group.
Different letters indicate significant differences among groups, P , 0.05, Fisher LSD post hoc
after significant ANOVA.

Furthermore, the percentage of epithelial cells expressing ERa was not affected in any
oxybenzone-treated group (Fig. 6C).
F. Oxybenzone Alters Expression of Progesterone Receptor in Mammary Epithelium
PR expression in the mammary gland is mediated by ERa [3], and thus, PR is often seen as a
measure of ERa functionality [59]. In the adult mammary gland, PR expression is scattered
throughout the epithelium; by late pregnancy, PR expression drops [60, 61]. It is absent in the
mammary epithelium during lactation, and expression returns during involution [2, 6, 62].
Because we observed that parity altered expression of Esr1, and oxybenzone produced an
intermediate phenotype, we next evaluated the effects of these factors on expression of PR.
PR mRNA was not affected by either oxybenzone or parity (Fig. 6D). However, analysis of PR
protein expression revealed an effect of both parity and oxybenzone on PR-positive epithelial
cells (Fig. 6E). Similar to what was seen with Esr1 expression, parity significantly decreased
the fraction of PR-positive cells compared with the nulliparous glands (P , 0.05, Fisher LSD;
Fig. 6F). This decreased percentage of PR-positive cells was also observed for the oxybenzoneTDI mammary glands, (P , 0.05, Fisher LSD). Conversely, in the oxybenzone-95P- and
oxybenzone-NOAEL-treated females, the diminished expression of PR associated with parity
was no longer observed, consistent with an intermediate phenotype.
G. Oxybenzone Does Not Affect ERb-Mediated Gene Expression
The role of ERb in the mammary gland at different stages of development has been debated,
largely as a result of difficulty identifying antibodies that are specific to this isoform [63].
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Figure 6. Oxybenzone alters Esr1 and PR in the mammary gland. (A) Expression of Esr1, the
gene encoding ERa, in the mammary gland reveals an intermediate phenotype for all three
treated groups. (B) Mammary gland sample after an immunohistochemistry for ERa expression.
Original scale bars, 20 mm; red arrows indicate positive cells. (C) Quantification of ERa expression
in mammary gland samples reveals no effects of parity or oxybenzone treatment. (D) mRNA
expression of PR (total) in the mammary gland reveals no differences among treatment groups.
(E) Immunohistochemistry for PR. Original scale bars, 20 mm; red arrows indicate positive cells.
(F) Quantification of PR expression in mammary tissue reveals an intermediate phenotype in the
oxybenzone-95P and oxybenzone-NOAEL treatment groups. In all panels, different letters indicate
significant differences among groups, P , 0.05, Fisher LSD post hoc after significant ANOVA.
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Although some studies have suggested that ERb is highly expressed in mammary epithelium
in adulthood, pregnancy, and lactation [64], others fail to detect Esr2, the gene encoding ERb,
in this tissue [65]. With the use of qRT-PCR, no Ct values were observed for Esr2 in any
mammary sample; Esr2 was detected in ovary, suggesting that ERb was not expressed in any
mammary glands, regardless of parity (data not shown). To determine if oxybenzone alters
ERb-mediated gene expression, we evaluated the expression of Wnt5a, a gene that is
upregulated when ERb is expressed in mammary cells [66]. No substantial differences were
observed between any groups for Wnt5a gene expression (Fig. 7A). Likewise, qualitative
evaluations of Wnt5a protein expression in both the stromal and epithelial compartments of
the mammary gland did not reveal any differences in expression based on parity or oxybenzone exposure (Fig. 7B–7D). Expression of other ERb-mediated genes, including CCAAT/
enhancer-binding protein delta and TGF-b2 [66], was also not affected by oxybenzone exposures (data not shown).

3. Discussion
In this study, we examined mammary glands from female mice exposed to three doses of
oxybenzone during pregnancy and lactation and observed long-lasting effects of exposure on
the morphology, histology, and molecular profiles of the mammary glands. We compared the
oxybenzone-exposed animals with parous vehicle-exposed animals, as well as nulliparous
females, to evaluate whether oxybenzone exposure interfered with the reorganization of the
mammary gland that is characteristic of pregnancy, lactation, and involution. As expected,
ductal density was significantly increased in the parous vehicle-exposed females compared
with the nulliparous females. We found that the highest dose of oxybenzone permanently

Figure 7. Oxybenzone does not alter Wnt5a gene or protein expression. (A) Expression of
Wnt5a, a gene downstream of ERb, is unaffected by parity or oxybenzone treatment. (Esr2,
the gene encoding ERb, produced no CT values using qRT-PCR.) (B) Immunohistochemistry
for Wnt5a, a gene downstream of ERb. Original scale bar, 50 mm. (C) Quantification of
Wnt5a expression in the epithelium of the mammary gland using qualitative scores from 0
to 3 for relative expression reveals no significant differences among treatment groups. (D)
Quantification of Wnt5a expression in the mammary stroma using a qualitative scale reveals
no substantial differences associated with parity or oxybenzone exposure.
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altered the morphology of the mammary gland, as measured in the whole mount, indicative of
changes in the three-dimensional organization of this tissue. The substantial reduction in
ductal density in these females produced an intermediate phenotype resembling a mix
between the nulliparous and vehicle mammary glands (Fig. 4A). Additional studies are
needed to determine if this intermediate phenotype is a result of oxybenzone-induced reorganization of the mammary gland in pregnancy (e.g., limited proliferation), in lactation
(e.g., incomplete differentiation of lobuloalveolar structures), or during the processes of involution (e.g., excessive apoptosis and clearing of epithelial structures).
We also observed changes to the histomorphology of the mammary glands; similar to
ductal density evaluated in whole mounts, the amount of epithelium quantified in H&E
sections increased with parity in vehicle-exposed animals. In these two-dimensional views of
the mammary gland, females from the oxybenzone-TDI group were not significantly different
from either the nulliparous or the parous vehicle-exposed females, again consistent with an
intermediate phenotype (Fig. 4C). Collectively, these results suggest that the effects of exposures to this compound during pregnancy and lactation can have long-lasting effects on the
morphology of the mammary gland. Importantly, these results do not indicate whether the
mammary gland is the direct target of oxybenzone exposure or if the effects that we have
observed are a result of long-term alterations to the hypothalamic-pituitary-ovarian axis.
Full-term pregnancies in early adulthood can decrease breast cancer risk by up to 50% [25,
67–69]. In nulliparous animals given estrogen and progesterone, this same protection is also
induced, suggesting that the protection from pregnancy is hormonally controlled [67]. It is
suspected that this protection comes from the activity of tumor-suppressor genes, as well as the
interplay between ERa and ERb. ERa, when bound to estrogen, can activate transcription of
downstream targets, inducing growth and differentiation of epithelium. In contrast, ERb is
considered to have inhibitory behavior on proliferation, increasing genomic surveillance and
increasing the expression of tumor suppressor pathways, such as p53 [66, 67, 70–75]. In fact,
parous animals have a stronger response to DNA damage and more p53 tumor suppressor
action to enhance genomic surveillance [76–78]. This suggests that a chemical that binds ERa,
such as oxybenzone, may induce different, and perhaps even contradictory, effects compared
with a chemical that binds to ERb. Pregnancy is also protective against carcinogen-induced
mammary cancer [76]. One study in mice demonstrated that pregnancy induced downregulation of growth factor genes and upregulation of growth-inhibitory molecules, such as
TGF-b3 [76]. Pregnancy also induces more differentiation of the mammary gland and persistent changes in hematopoietic cells in the mammary gland [76], leading some researchers to
suggest that differentiation of mammary tissues may play a role in the protection from breast
cancer [22]. Even when controlling for age of first pregnancy, a protective effect of lactation on
breast cancer has been observed in women [79], with increased protection associated with
longer duration of lactation [80]. Future studies will examine if exposures to oxybenzone during
pregnancy and lactation alter cancer risk in mice. If diminished differentiation of mammary
epithelium associated with some doses of oxybenzone suggest a loss of some of the protective
effect of pregnancy, then it is also possible that these females will be more sensitive to chemicalinduced carcinogenesis. Additional studies are needed to evaluate this hypothesis.
In parous rats and mice, ERa-positive epithelial cells are reduced in the mammary gland, and
less proliferation is observed [81–84]. Here, we observed no effects of either parity or oxybenzone
exposure on the fraction of ERa-positive cells in mammary epithelium, although parity did
decrease the expression of Esr1 expression in the mammary gland (Fig. 6). Proliferation was also
affected by oxybenzone exposure, with a substantial increase in the highest dose group (Fig. 5).
Because oxybenzone is an ERa agonist, and ERa promotes mammary epithelial proliferation, it
is possible that this finding is a result of downstream ERa action, although it is surprising that
this effect persisted for 5 weeks after exposures ceased. This, again, might indicate a direct effect
of oxybenzone on the mammary gland (e.g., by permanently changing the number of parityinduced epithelial cells [14]), or it might indicate an indirect effect on the mammary gland (e.g., by
altering the release of gonadotropin hormones and disrupting the hypothalamic-pituitaryovarian axis). Additional studies are needed to evaluate these possibilities.
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Finally, we examined gene and protein expression downstream from ERa and ERb. Parity
decreased the number of epithelial cells expressing PR, and an intermediate phenotype of expression was observed in the two higher doses of oxybenzone (Fig. 6E); no changes were observed
for PR gene expression. Because PR is downstream of ERa [3], it is possible that this effect may
have been induced by alterations in ERa action that occurred during exposure. We also evaluated
the effects of oxybenzone exposure on expression of Wnt5a, which is downstream of ERb. Although we were not able to detect Esr2 in mammary tissue, ERb agonists alter parity-associated
mammary gland phenotypes, consistent with indirect effects of ERb-mediated pathways on
mammary gland health (unpublished data). Qualitative expression of Wnt5a protein, as well as
Wnt5a gene expression, was unaffected by either parity or oxybenzone exposure. These results
are not particularly surprising considering oxybenzone’s actions as an ERa agonist.
It is important to note that the doses chosen for this study are not high doses. In all three
oxybenzone-treated groups, no overt signs of toxicity were observed (e.g., no changes to the
number of pups, pup survival, or dam weight gain; Fig. 2). All three doses are at or below the
toxicological NOAEL dose, and reproductive toxicity is reported at much higher doses (25 to
45 mg/kg) [50]. We selected doses to replicate exposures at which no adverse effects were
previously reported (the NOAEL dose), a dose that reflects exposures in pregnant women (the
95P dose), and the TDI dose. Other groups have found that applied doses, ~10-fold higher
than the highest dose administered here, are needed to replicate human urinary concentrations (see [48] and unpublished data). Thus, the results that we observed are concerning,
as they are occurring at doses that are relevant for regulation of this compound and/or for
exposed humans [85]. Importantly, acute exposures to the NOAEL dose did not induce a
uterotrophic response, although they did alter expression of Esr1 in the uterus (Fig. 2). These
results are consistent with prior studies indicating that oxybenzone is estrogenic but with
lower potency than other known estrogenic endocrine disruptors [58]. However, it cannot be
discounted that the effects of oxybenzone on the mammary gland when exposures occur
during pregnancy and lactation could be a result of mechanisms distinct from ERa. Additional studies are needed to evaluate this possibility. Another potential limitation of the
study is the route of exposure; humans are largely exposed to oxybenzone dermally via
personal care products. Our animals were exposed orally, which may allow the chemical to be
metabolized by the liver before entering circulation, unlike uptake via dermal exposures,
where oxybenzone can enter circulation and reach organs before metabolism [45]; thus, our
exposures may underestimate those experienced by pregnant women.
Studies by Alonso-Magdalena et al. [37] showed that low-dose BPA exposures induced
metabolic disruptions in male offspring exposed during gestation but also in their mothers
exposed during pregnancy; these effects manifested long after exposures ended. This study
challenged the long-held belief that low-dose xenoestrogens would not affect the health of the
mother as a result of high concentrations of circulating estrogens. Our study similarly suggests
that oxybenzone exposure during pregnancy and lactation can affect the maternal mammary
gland after involution, and these effects can be permanent, consistent with the organizational
role of hormones during critical windows of development. Collectively, these results indicate
that pregnancy and lactation should be considered a vulnerable period of susceptibility to
xenoestrogens, not just for the developing fetus and neonate but also for her mother as well.
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